文献速递妇科

腹腔镜作为卵巢癌初次肿瘤细胞减灭术前诊断工具的成本效果分析

Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2017-06-20

在疑似晚期卵巢癌患者中开展随机对照试验的经济学分析,比较先行诊断性腹腔镜与直接初次肿瘤细胞减灭术。腹腔镜将无效剖腹术从39%降至10%,每例干预成本1400欧元,两组总直接医疗成本相当(每例差异-80欧元,95%CI -470至300),QALYs无显著差异。

要点

  • 疑似晚期卵巢癌患者先行诊断性腹腔镜可减少无效剖腹术。
  • 腹腔镜每例干预成本1400欧元,两组总直接医疗成本相当。
  • QALYs无显著差异,效用值差异0.01(95%CI 0.006至0.02)。

核心结论

  • 在疑似晚期卵巢癌患者中,诊断性腹腔镜减少了无效剖腹术的数量,且未增加总直接医疗保健成本,也未对并发症或生活质量产生不利影响。

研究设计与样本

  • 一项随机对照试验的经济学分析,患者为符合初次肿瘤细胞减灭术条件的疑似晚期卵巢癌患者,随机分为腹腔镜组或初次肿瘤细胞减灭术组。
  • 共纳入201例患者,其中102例随机至腹腔镜组,99例随机至初次肿瘤细胞减灭术组。
  • 从医疗保健视角分析6个月时间范围直接医疗成本,成本基于荷兰标准价格。
  • 健康结局以质量调整生命年(QALYs)表示,效用基于患者对EQ-5D问卷的回答。

主要发现

  • QALYs无显著差异,效用值差异为0.01(95%CI 0.006至0.02)。
  • 腹腔镜将无效剖腹术从39%降至10%。
  • 腹腔镜每例干预成本为1400欧元,两组总成本相当,每例差异为-80欧元(95%CI -470至300)。
  • 各项敏感性分析结果一致。

临床怎么用

  • 作者结论认为,在疑似晚期卵巢癌患者中,诊断性腹腔镜可减少无效剖腹术,且不增加总直接医疗保健成本,也不对并发症或生活质量产生不利影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the cost-effectiveness of a diagnostic laparoscopy prior to primary cytoreductive surgery to prevent futile primary cytoreductive surgery (i.e. leaving >1cm residual disease) in patients suspected of advanced stage ovarian cancer. METHODS: An economic analysis was conducted alongside a randomized controlled trial in which patients suspected of advanced stage ovarian cancer who qualified for primary cytoreductive surgery were randomized to either laparoscopy or primary cytoreductive surgery. Direct medical costs from a health care perspective over a 6-month time horizon were analyzed. Health outcomes were expressed in quality-adjusted life-years (QALYs) and utility was based on patient's response to the EQ-5D questionnaires. We primarily focused on direct medical costs based on Dutch standard prices. RESULTS: We studied 201 patients, of whom 102 were randomized to laparoscopy and 99 to primary cytoreductive surgery. No significant difference in QALYs (utility=0.01; 95% CI 0.006 to 0.02) was observed. Laparoscopy reduced the number of futile laparotomies from 39% to 10%, while its costs were € 1400 per intervention, making the overall costs of both strategies comparable (difference € -80 per patient (95% CI -470 to 300)). Findings were consistent across various sensitivity analyses. CONCLUSION: In patients with suspected advanced stage ovarian cancer, a diagnostic laparoscopy reduced the number of futile laparotomies, without increasing total direct medical health care costs, or adversely affecting complications or quality of life.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. van de Vrie R, van Meurs HS, Rutten MJ, et al. Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer. Gynecol Oncol. 2017. PMID: 28645428. doi:10.1016/j.ygyno.2017.06.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。